GlaxoSmithKline has posted double-digit growth - test
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has posted double-digit growth in both its first-quarter turnover and EPS as strong performances from its vaccines business and from emerging markets, Asia and Europe more than offset a slight decline in sales in the US.